About
The 2023 Event Has Run: Thank You to Our Speakers, Sponsors and Delegates for Joining Us at the Meeting!
Welcome to the Retinal Vascular Disease Drug Development Summit: The Only Industry-Focused Meeting for Wet AMD, DME, DR and RVO Therapeutic Development
Retinal Vascular Disease Drug Development Summit is an event dedicated to creating a community space dedicated to overcoming the current challenges in drug development for retinal vascular diseases.
The management of these diseases has made remarkable advancements in previous years, but the burden on patients remains high, posing a need to develop novel therapeutics and delivery mechanisms that improve the efficacy and durability of anti-VEGF drugs and beyond.
Providing you with an in-depth coverage of technical insights of anti-VEGF, innovative non-VEGF targeting therapeutics for wet-AMD, DME, DR and RVO, the Retinal Vascular Disease Drug Development Summit will address the specific challenges in utilizing preclinical models for retinal vascular disease, understand key regulatory requirements, and learn how to run effective clinical trials that utilize appropriate endpoints.
Join your colleagues from across R&D, preclinical, translational and clinical teams across the biopharmaceutical industry to streamline your drug development and address the significant and increasing unmet medical need.
Join Your Peers to:
Overcome challenges associated with preclinical models and their translatability with Novartis and the National Eye Institute to improve the outcomes of your clinical trials
Learn about novel delivery mechanisms and mechanisms of action with OcuTerra to help reduce the burden to your patients
Discover updates in the development of anti-VEGF therapeutics with the Mayo Clinic to gain an understanding of developments in efficacy and durability
Explore development in novel therapeutics beyond anti-VEGF with Genentech and InflammX to aid your understanding of the current landscape and inspire innovation
Gain insights into better methods of patient selection and improved clinical biomarkers and endpoints for development trials with Biogen to improve outcomes of your clinical trials
Who Will You Meet?
Join your colleagues from R&D, Preclinical, Translational and Clinical teams at the pharmaceutical and biotech companies actively developing these therapeutics to streamline your drug development pipeline and address the significant and increasing unmet need.
What Your Peers Have to Say
